ClinicalTrials.gg
RecruitingNCT06421155Updated Oct 20, 2026

Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia

An interventional study of MRF with neurocognative studies in Acute Leukemia, Acute Lymphoblastic Leukemia, Pediatric and Acute Myeloid Leukemia in Children, sponsored by Case Comprehensive Cancer Center. Recruiting at 1 site in United States. Open to participants aged Up to 30 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Case Comprehensive Cancer Center · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.
Updated Oct 20, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
Up to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 32 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Case Comprehensive Cancer Center — 2 open to participants now, 2 under way, none of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · Case Comprehensive Cancer Center.

Planned enrollment
17th of 28
20 · median 28
Started
2024
the only one that year
No phase
3 of 32
1 open now
Registered
31st of 32
by date

Among the 32 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Case Comprehensive Cancer Center, this one is the 17th largest by planned enrollment of the 28 interventional ones that give a count, is the only one that started in 2024, is one of 3 with no phase, and was the 31st registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

2 of the 32 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Case Comprehensive Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: Up to 30 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Case Comprehensive Cancer Center, or all of them as a file.
02

Study summary

The survival of children, adolescents and young adults (AYA) with acute leukemia has improved dramatically over the last two decades. This success is a result of using multiple chemotherapy drugs in combination, with the inclusion of drugs that enter the brain and prevent leukemia cells from growing there. Studies in these cancer survivors have shown that the exposure to these chemotherapy drugs can lead to risks for impaired brain function, also referred to as neurocognitive side effects of chemotherapy. There is an opportunity to identify participants at risk for these side effects and to prevent their development. The purpose of this study is to incorporate a brain imaging tool known as Magnetic Resonance Fingerprinting (MRF) to look for brain matter changes in acute leukemia participants receiving chemotherapy. The MRF scan will be performed at diagnosis and repeated at multiple times during the entire therapy duration as well as at defined intervals after therapy is complete. Investigators would also do an electronic test of memory and brain function (cognitive function), which would be administered in a gaming format on iPads or a similar device. The goal will be to correlate results of MRF imaging with the tests of cognitive function. The benefits of this imaging technique include that it can be done quickly (in minutes), it is non-invasive, it is resistant to motion-artifacts and it can be easily repeated for comparison purposes. The advantages of the cognitive test include its short duration of 20 minutes and its gaming format making it friendly for children to use.

Read the detailed description

Acute leukemia (AL), including Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML) and myeloproliferative neoplasms (MPN) are among the most common childhood cancers, the 5-year overall survival of children with leukemia has significantly improved with the current treatment methods, and is now \~90 % for ALL participants and \~70 % for AML participants. There has been a remarkable shift in the treatment strategy for childhood acute leukemia to reduce the burden of therapy related complications. Most notably, the addition of central nervous system (CNS)-directed, intensified intravenous and intrathecal chemotherapy regimens for most standard risk participants has obviated the need for craniospinal radiation therapy (CRT), thus reserving CRT for high-risk participants. With the improved overall survival rates, there is an increasing focus on characterizing and mitigating the long-term effects of the disease and therapy that may affect the quality of life of these participants. The results of multiple studies have indicated that the long-term survivors of ALL and AML experience varying degrees of neurocognitive deficits including memory loss, poor concentration, deficits in executive functioning and personality changes5-9. Methotrexate which is an important chemotherapeutic agent in the treatment of acute leukemia is known to cause chemotherapy induced cognitive impairment (CICI), by causing complex glial dysfunction leading to disruption of activity-dependent myelination in the CNS.

Studies designed to characterize normal brain development in early childhood have not only contributed significantly to our understanding of healthy neurodevelopment, but have also helped to identify neurodevelopmental problems at an early stage, enabling the application of treatment interventions in a timely fashion. Although magnetic resonance imaging (MRI) has been used for this purpose, its application has been hampered by several limitations including the sensitivity to motion artifact, the length of time required to perform a scan, and the requirement for sedation for younger participants. These limitations can be overcome using a new technology known as magnetic resonance fingerprinting (MRF), which allows for rapid, efficient and simultaneous quantification of multiple tissue properties, and quantifies T1, T2 and Myelin Water Fraction (MWF) simultaneously. Sedation is not necessary since whole brain MRF imaging takes approximately 5 minutes to complete and is resistant to motion artifacts.

These properties position MRF for use to assess multiple tissue properties in both pediatric and AYA participants diagnosed with acute leukemia, before, during and after exposure to CNS directed chemotherapy. The investigator proposes to use MRF to monitor demyelination, which has been documented as an underlying mechanism contributing to the long-term neurocognitive deficits seen in participantsundergoing chemotherapy. The goal of using MRF in this context is that it might ultimately serve as a valuable imaging biomarker that would enable early detection of the participants that are at an increased risk of developing neurocognitive deficits due to exposure to anti-neoplastic chemotherapy, by detecting the myelin changes as defined by MRF quantification of myelin water fraction. The capacity for detection would facilitate development of early interventions for these high-risk participants, so that their quality of life can be preserved as much as possible.

The study will evaluate the feasibility of obtaining MRF imaging data along with assessments of neurocognitive function. Chanages/decline in neurocognitive function in pediatric participants undergoing treatment for acute leukemia have been tested, validated and reported by the Children's Oncology Group using a battery of assessment developed by Cogstate®. The computerized cognitive tests are rapid, reliable, and have demonstrated sensitivity to drug related changes in cognition. The tests have been designed and validated to withstand operational challenges during the conduction of clinical trials. The data system is HIPAA compliant U.S. FDA Class II Exempt Digital Medical Device.

03

Conditions studied

  • Acute Leukemia
  • Acute Lymphoblastic Leukemia, Pediatric
  • Acute Myeloid Leukemia in Children
  • Myeloproliferative Neoplasm

Keywords

  • Acute Leukemia Children
  • Acute Leukemia Adolescents
  • Acute Leukemia Young Adults
04

Who can participate

Ages eligible
Up to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age range: 0 - 30 years
  • Participants from University Hospitals Rainbow Babies \& Children's Hospital, UH Seidman Cancer Center, and participants referred from outside facilities diagnosed with acute leukemia.
  • Meets diagnostic criteria for acute leukemia including acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML) and myeloproliferative neoplasm/leukemia.
  • Participants must have the ability to understand and the willingness to sign a written document. Participants who are 14 years and older must have the ability to understand and the willingness to sign a written informed consent document. Participants who are between the ages of 7 to 13 will be given an information sheet that explains the study to them. The information sheet may be used for study participants between the ages of 14-17 if it would better inform the child about the nature and procedures that will undergo as a participant in the study.

Exclusion criteria

Exclusion Criteria:

  • Individuals that are >2 weeks into the induction chemotherapy for acute leukemia.
  • Individuals with either a heart pacemaker, heart defibrillator, metal in the eye, some types of metal elsewhere within the body such as certain surgical clips for aneurysms in the head, heart valve prostheses, electrodes, some other implanted devices, or any other MRI
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Other
    MRF +/-Neurocognitive Testing

    Once the participants meeting the inclusion criteria are identified and formally consent to participate in the study, each participant will undergo a baseline MRF imaging exam along with the neurocognative testing, preferably prior to starting induction chemotherapy. The total treatment duration for an individual participant can vary anywhere between 6 months - 3 years depending on the type of acute leukemia, so investigator plans to obtain MRF scans every 6 months during the therapy as well as during the first year of the off -therapy period

    Other: MRF with neurocognative studies

Interventions

  • OtherMRF with neurocognative studies

    Magnetic Resonance Imaging is used to assess the risk of neurocognitive side effects in pediatric and AYA patients with acute leukemia receiving chemotherapy and participants will also be asked to complete a neurocognitive battery designed by Cogstate and administered on iPad in a simple gaming format

06

What researchers measure

Primary outcomes

  1. Incidence of alterations in brain structure as measured by mean myelin water fraction

    Mean myelin water fraction is measured by Student's T-test. The two-tailed means comparison will be considered statistically significant if a p-value of less than 0.5 is observed.

    Time frame: Baseline and during chemotherapy(up to 3.5 years)

Secondary outcomes

  1. Incidence of change in tissue evaluation using brain property mapping

    Brain tissue property maps assessed using MRF scans

    Time frame: Baseline, every 6 months during the duration of therapy(up to 3.5 years), and every 6 months during the first year of the off-therapy period.

Other outcomes

  1. Incidence of brain tissue changes using neurocognitive testing

    Cognitive assessment using Cogstate software

    Time frame: Baseline, every 6 months during the duration of therapy(up to 3.5 years), and every 6 months during the first year of the off-therapy period.

07

Study locations

1 of 1 sites recruiting
  • University Hospitals Cleveland Medical Center, Rainbow Babies & Children's Hospital, Case Comprehensive Cancer Center
    Cleveland, Ohio 44106, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Clinical diagnosis, treatment, MRI/MRF and neurocognitive testing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data will be provided within 12 months from study completion and for at least 6 years after study closure.

Access criteria: Study team will only have access to submit data

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Jun 2027, 32 months after the start.

Of 207 non-industry interventional studies with no phase under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 66. This study's planned 32 months is close to that.

Counting every sponsor, half of 214 studies reached it within 32 months; a quarter within 12 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2024
First posted
May 20, 2024
StartActual
Oct 4, 2024
Primary completionEst.
Jun 14, 2027
CompletionEst.
Jun 14, 2028
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Suspended→Recruiting Reason for stopping removed
changed Oct 20, 2026
Sites
University Hospitals Cleveland Medical Center, Rainbow Babies & Children's Hospital, Case Comprehensive Cancer Center is now Recruiting
Oct 20, 2026
Contact
Study contact now listed: added A•••@uhhospitals.org · •••1404. See the current contact
Oct 20, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • University Hospitals Cleveland Medical Center, Rainbow Babies & Children's Hospital, Case Comprehensive Cancer Center · Cleveland, United StatesContact added A•••@uhhospitals.org · •••1404Contact added (no phone or email listed)
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Suspended→Recruiting
    Why stopped Reason for stopping removed
    University Hospitals Cleveland Medical Center, Rainbow Babies & Children's Hospital, Case Comprehensive Cancer Center is now Recruiting
    Contact Study contact now listed: added A•••@uhhospitals.org · •••1404. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University Hospitals Cleveland Medical Center, Rainbow Babies & Children's Hospital, Case Comprehensive Cancer Center · Cleveland, United StatesContact added A•••@uhhospitals.org · •••1404Contact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06421155
Responsible party
Sponsor
First posted
May 20, 2024
Start date
Oct 4, 2024
Primary completion
Jun 14, 2027 (estimated)
Completion
Jun 14, 2028 (estimated)
Last update
Oct 20, 2026

Study contacts

Anupam Verma, MD
Contact
Anupam.verma@uhhospitals.org
216-844-1404
Anupam Verma, MD
principal investigator · University Hospitals Cleveland Medical Center, Rainbow Babies & Children's Hospital, Case Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion